Fielder Capital Group’s Alaunos Therapeutics TCRT Stock Holding History

Fielder Capital Group’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-100	Closed	-$1.06K	–	176
2023 Q4	$1.06K	Buy	+100	New	+$1.2K	﹤0.01%	146

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Fielder Capital Group's TCRT Position: Q1 2024 in Review

Fielder Capital Group sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 100 shares — an estimated $1.06K sold.

Fielder Capital Group first reported a position in TCRT in Q4 2023 and held it in 1 quarter. The position peaked at $1.06K in Q4 2023. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

Fielder Capital Group reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
Fielder Capital Group sold 100 Alaunos Therapeutics shares in Q1 2024, an estimated $1.06K.
Fielder Capital Group first reported a position in Alaunos Therapeutics in Q4 2023 and held it in 1 quarter.
Fielder Capital Group's Alaunos Therapeutics position peaked at $1.06K in Q4 2023.
45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on Fielder Capital Group's 13F filing for Q1 2024, filed 25 Apr 2024.